[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553458":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":15,"responsibleParty":31,"collaborators":7,"id":35,"slug":7,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":7,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":7,"enrollmentInfo":43,"targetDuration":7,"studyType":46,"phases":7,"briefSummary":47,"conditions":48,"keywords":50,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},{"fullName":5,"class":6},"Fujian Medical University Union Hospital","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":13,"email":14},"Huifang Huang","CONTACT","13365910318","0591-86218641","huanghuif@fjmu.edu.cn",[16],{"facility":5,"status":17,"city":18,"state":19,"zip":20,"country":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"RECRUITING","Fuzhou","Fujian","350001","China",{"type":23,"coordinates":24},"Point",[25,26],119.30611,26.06139,{"lat":26,"lon":25},[29],{"name":30,"role":11,"phone":12,"phoneExt":13,"email":14},"huifang huang",{"type":32,"investigatorFullName":33,"investigatorTitle":34,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Huifang Huang, MD","Professor","100553458",false,"NCT06486350","IL-6: A Marker for AML Chemo Sensitivity","Bone Marrow Supernatant IL-6 as a Predictor of Chemotherapy Sensitivity in AML Patients","Inclusion Criteria:\n\n1. Clinical diagnosis aligns with the \"Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)\";\n2. All patients are experiencing their first onset of the disease and have not received any related chemotherapy prior to the study;\n3. Patients participate in the study accompanied by family members and sign informed consent documents.\n\nExclusion Criteria:\n\n1. Patients with concurrent malignancies requiring treatment;\n2. Presence of infectious diseases, including SARS, viral hepatitis, or HIV\u002FAIDS;\n3. Major surgery performed within the last 21 days;\n4. Performance Status (PS) score \\>3;\n5. Severe liver or kidney dysfunction or serious infection;\n6. Severe psychiatric conditions that impair understanding of the study protocol or voluntary withdrawal.","ALL","18 Years",{"count":44,"type":45},72,"ESTIMATED","OBSERVATIONAL","Acute myeloid leukemia (AML) is a clonal malignancy that arises from the primitive hematopoietic cells within the hematopoietic system. According to SEER cancer statistics, the 5-year survival rate for AML patients stands at a concerning 30%. Despite therapeutic advancements, the development of chemotherapy resistance and the risk of disease relapse pose significant barriers to curative outcomes. Evidence has linked elevated interleukin-6 (IL-6) levels in plasma and bone marrow to a poorer prognosis in AML, with IL-6 potentially fostering chemotherapy resistance through the enhancement of fatty acid uptake and the induction of stromal-like morphological changes in AML cells. However, the role of IL-6 as a potential biomarker for monitoring chemotherapy sensitivity in AML has not been fully elucidated. This study seeks to investigate the correlation between IL-6 levels in bone marrow supernatant and the sensitivity to chemotherapy, offering a clinical perspective that could pave the way for improved prognostic markers and personalized treatment strategies.",[49],"AML, Adult",[51,52,53],"AML","IL-6","Chemotherapy sensitivity","2024-06-30",{"date":56,"type":57},"2024-07-03","ACTUAL",{"date":59,"type":57},"2023-10-01",{"date":61,"type":45},"2025-06",{"name":5,"class":6},1]